Screening for biological response modifiers: methods and rationale
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Boston u.a.
Nijhoff
1985
|
| Schriftenreihe: | Developments in oncology
29 |
| Schlagworte: | |
| Beschreibung: | XIII, 193 S. |
| ISBN: | 0898387124 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV000304507 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 870612s1985 |||| 00||| eng d | ||
| 020 | |a 0898387124 |9 0-89838-712-4 | ||
| 035 | |a (OCoLC)11756240 | ||
| 035 | |a (DE-599)BVBBV000304507 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 050 | 0 | |a RC271.I45 | |
| 082 | 0 | |a 616.99/4061 |2 19 | |
| 100 | 1 | |a Talmadge, James E. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Screening for biological response modifiers |b methods and rationale |c James E. Talmadge ; Isaiah J. Fidler ; Robert K. Oldham |
| 264 | 1 | |a Boston u.a. |b Nijhoff |c 1985 | |
| 300 | |a XIII, 193 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Developments in oncology |v 29 | |
| 610 | 2 | 4 | |a Biological Response Modifier Program (U.S.) |
| 650 | 4 | |a Adjuvants, Immunologic |x therapeutic use | |
| 650 | 4 | |a Antineoplastic Agents |x therapeutic use | |
| 650 | 4 | |a Antineoplastic agents | |
| 650 | 4 | |a Biological products |x Testing | |
| 650 | 4 | |a Biological response modifiers | |
| 650 | 4 | |a Cancer |x Immunological aspects | |
| 650 | 4 | |a Drug Evaluation, Preclinical |x methods | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Neoplasms |x therapy | |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Tierversuch |0 (DE-588)4060137-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Biological response modifier |0 (DE-588)4475179-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakologie |0 (DE-588)4045687-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Chemotherapie |0 (DE-588)4127083-6 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Chemotherapie |0 (DE-588)4127083-6 |D s |
| 689 | 0 | 2 | |a Tierversuch |0 (DE-588)4060137-7 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 1 | 1 | |a Biological response modifier |0 (DE-588)4475179-5 |D s |
| 689 | 1 | 2 | |a Pharmakologie |0 (DE-588)4045687-0 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Fidler, Isaiah J. |e Verfasser |4 aut | |
| 700 | 1 | |a Oldham, Robert K. |e Verfasser |4 aut | |
| 830 | 0 | |a Developments in oncology |v 29 |w (DE-604)BV036830146 |9 29 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-000185937 | ||
Datensatz im Suchindex
| _version_ | 1804114769122164736 |
|---|---|
| any_adam_object | |
| author | Talmadge, James E. Fidler, Isaiah J. Oldham, Robert K. |
| author_facet | Talmadge, James E. Fidler, Isaiah J. Oldham, Robert K. |
| author_role | aut aut aut |
| author_sort | Talmadge, James E. |
| author_variant | j e t je jet i j f ij ijf r k o rk rko |
| building | Verbundindex |
| bvnumber | BV000304507 |
| callnumber-first | R - Medicine |
| callnumber-label | RC271 |
| callnumber-raw | RC271.I45 |
| callnumber-search | RC271.I45 |
| callnumber-sort | RC 3271 I45 |
| callnumber-subject | RC - Internal Medicine |
| ctrlnum | (OCoLC)11756240 (DE-599)BVBBV000304507 |
| dewey-full | 616.99/4061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4061 |
| dewey-search | 616.99/4061 |
| dewey-sort | 3616.99 44061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02208nam a2200601 cb4500</leader><controlfield tag="001">BV000304507</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">870612s1985 |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0898387124</subfield><subfield code="9">0-89838-712-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)11756240</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV000304507</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC271.I45</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/4061</subfield><subfield code="2">19</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Talmadge, James E.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Screening for biological response modifiers</subfield><subfield code="b">methods and rationale</subfield><subfield code="c">James E. Talmadge ; Isaiah J. Fidler ; Robert K. Oldham</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boston u.a.</subfield><subfield code="b">Nijhoff</subfield><subfield code="c">1985</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIII, 193 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Developments in oncology</subfield><subfield code="v">29</subfield></datafield><datafield tag="610" ind1="2" ind2="4"><subfield code="a">Biological Response Modifier Program (U.S.)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adjuvants, Immunologic</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Agents</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biological products</subfield><subfield code="x">Testing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biological response modifiers</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Immunological aspects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Evaluation, Preclinical</subfield><subfield code="x">methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Tierversuch</subfield><subfield code="0">(DE-588)4060137-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Biological response modifier</subfield><subfield code="0">(DE-588)4475179-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Tierversuch</subfield><subfield code="0">(DE-588)4060137-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Biological response modifier</subfield><subfield code="0">(DE-588)4475179-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Pharmakologie</subfield><subfield code="0">(DE-588)4045687-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fidler, Isaiah J.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oldham, Robert K.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Developments in oncology</subfield><subfield code="v">29</subfield><subfield code="w">(DE-604)BV036830146</subfield><subfield code="9">29</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-000185937</subfield></datafield></record></collection> |
| id | DE-604.BV000304507 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T15:11:59Z |
| institution | BVB |
| isbn | 0898387124 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-000185937 |
| oclc_num | 11756240 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | XIII, 193 S. |
| publishDate | 1985 |
| publishDateSearch | 1985 |
| publishDateSort | 1985 |
| publisher | Nijhoff |
| record_format | marc |
| series | Developments in oncology |
| series2 | Developments in oncology |
| spelling | Talmadge, James E. Verfasser aut Screening for biological response modifiers methods and rationale James E. Talmadge ; Isaiah J. Fidler ; Robert K. Oldham Boston u.a. Nijhoff 1985 XIII, 193 S. txt rdacontent n rdamedia nc rdacarrier Developments in oncology 29 Biological Response Modifier Program (U.S.) Adjuvants, Immunologic therapeutic use Antineoplastic Agents therapeutic use Antineoplastic agents Biological products Testing Biological response modifiers Cancer Immunological aspects Drug Evaluation, Preclinical methods Immunotherapy Neoplasms therapy Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Tierversuch (DE-588)4060137-7 gnd rswk-swf Biological response modifier (DE-588)4475179-5 gnd rswk-swf Pharmakologie (DE-588)4045687-0 gnd rswk-swf Chemotherapie (DE-588)4127083-6 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 s Chemotherapie (DE-588)4127083-6 s Tierversuch (DE-588)4060137-7 s DE-604 Biological response modifier (DE-588)4475179-5 s Pharmakologie (DE-588)4045687-0 s Fidler, Isaiah J. Verfasser aut Oldham, Robert K. Verfasser aut Developments in oncology 29 (DE-604)BV036830146 29 |
| spellingShingle | Talmadge, James E. Fidler, Isaiah J. Oldham, Robert K. Screening for biological response modifiers methods and rationale Developments in oncology Biological Response Modifier Program (U.S.) Adjuvants, Immunologic therapeutic use Antineoplastic Agents therapeutic use Antineoplastic agents Biological products Testing Biological response modifiers Cancer Immunological aspects Drug Evaluation, Preclinical methods Immunotherapy Neoplasms therapy Krebs Medizin (DE-588)4073781-0 gnd Tierversuch (DE-588)4060137-7 gnd Biological response modifier (DE-588)4475179-5 gnd Pharmakologie (DE-588)4045687-0 gnd Chemotherapie (DE-588)4127083-6 gnd |
| subject_GND | (DE-588)4073781-0 (DE-588)4060137-7 (DE-588)4475179-5 (DE-588)4045687-0 (DE-588)4127083-6 |
| title | Screening for biological response modifiers methods and rationale |
| title_auth | Screening for biological response modifiers methods and rationale |
| title_exact_search | Screening for biological response modifiers methods and rationale |
| title_full | Screening for biological response modifiers methods and rationale James E. Talmadge ; Isaiah J. Fidler ; Robert K. Oldham |
| title_fullStr | Screening for biological response modifiers methods and rationale James E. Talmadge ; Isaiah J. Fidler ; Robert K. Oldham |
| title_full_unstemmed | Screening for biological response modifiers methods and rationale James E. Talmadge ; Isaiah J. Fidler ; Robert K. Oldham |
| title_short | Screening for biological response modifiers |
| title_sort | screening for biological response modifiers methods and rationale |
| title_sub | methods and rationale |
| topic | Biological Response Modifier Program (U.S.) Adjuvants, Immunologic therapeutic use Antineoplastic Agents therapeutic use Antineoplastic agents Biological products Testing Biological response modifiers Cancer Immunological aspects Drug Evaluation, Preclinical methods Immunotherapy Neoplasms therapy Krebs Medizin (DE-588)4073781-0 gnd Tierversuch (DE-588)4060137-7 gnd Biological response modifier (DE-588)4475179-5 gnd Pharmakologie (DE-588)4045687-0 gnd Chemotherapie (DE-588)4127083-6 gnd |
| topic_facet | Biological Response Modifier Program (U.S.) Adjuvants, Immunologic therapeutic use Antineoplastic Agents therapeutic use Antineoplastic agents Biological products Testing Biological response modifiers Cancer Immunological aspects Drug Evaluation, Preclinical methods Immunotherapy Neoplasms therapy Krebs Medizin Tierversuch Biological response modifier Pharmakologie Chemotherapie |
| volume_link | (DE-604)BV036830146 |
| work_keys_str_mv | AT talmadgejamese screeningforbiologicalresponsemodifiersmethodsandrationale AT fidlerisaiahj screeningforbiologicalresponsemodifiersmethodsandrationale AT oldhamrobertk screeningforbiologicalresponsemodifiersmethodsandrationale |